Article Text

Download PDFPDF

A lifestyle intervention or metformin prevented or delayed the onset of metabolic syndrome in persons at risk

Statistics from

 Q In persons with impaired glucose tolerance, does an intensive lifestyle intervention (ILS) or treatment with metformin plus standard lifestyle recommendations prevent onset or promote resolution of metabolic syndrome?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★☆☆ Endocrine ★★★★☆☆☆


Embedded ImageDesign:

randomised placebo controlled trial (The Diabetes Prevention Program randomised trial).

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded (clinicians, participants, data collectors, and outcome assessors for metformin and placebo).*

Embedded ImageFollow-up period:

mean 3.2 years.

Embedded ImageSetting:

27 centres in the US.

Embedded ImageParticipants:

3234 participants ⩾25 years of age (mean age 51y, 68% women) without diabetes who had a body mass index ⩾24 kg/m2 (⩾22 kg/m2 for Asian Americans) and a plasma glucose concentration 5.3–7.0 mmol/l (95–125 mg/dl) (⩽7.0 mmol/l [⩽125 mg/dl] for Native Americans) …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.